Aspen Explains U-Turn On Withdrawing From Proposed API Sale
As South African Firm Wraps Up Major COVID-19 Deal With J&J
Executive Summary
Following years of reshaping its operations, one part of Aspen Pharmacare’s business that is to stay for now is the firm’s API division. The South African firm’s management explained why as Aspen presented results from its financial first half, hours after wrapping up a key COVID-19 licensing deal with Johnson & Johnson.